Advaxis, Inc. (NASDAQ:ADXS)’s share price hit a new 52-week low on Wednesday . The stock traded as low as $2.74 and last traded at $2.93, with a volume of 428500 shares trading hands. The stock had previously closed at $2.97.

Several equities analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research report on Wednesday, November 8th. ValuEngine lowered shares of Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. Cantor Fitzgerald reissued a “buy” rating and issued a $19.00 price objective on shares of Advaxis in a research report on Monday, September 25th. Finally, BidaskClub raised shares of Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $3.43 million. equities research analysts forecast that Advaxis, Inc. will post -2.21 earnings per share for the current year.

In related news, CFO Sara Bonstein sold 12,734 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the transaction, the chief financial officer now directly owns 244,504 shares in the company, valued at $779,967.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $4.42, for a total transaction of $5,477,807.66. The disclosure for this sale can be found here. Insiders sold 1,872,291 shares of company stock worth $8,163,810 over the last 90 days. 7.21% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC grew its stake in shares of Advaxis by 20.3% in the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 2,975 shares in the last quarter. Northern Capital Management LLC grew its stake in Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock worth $135,000 after buying an additional 2,650 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Advaxis by 18.2% during the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock worth $168,000 after buying an additional 4,000 shares in the last quarter. Stonebridge Capital Management Inc. grew its stake in Advaxis by 88.7% during the third quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock worth $179,000 after buying an additional 20,045 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Advaxis during the second quarter worth about $201,000. Institutional investors and hedge funds own 41.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/advaxis-adxs-sets-new-12-month-low-at-2-74.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Receive News & Stock Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related stocks with our FREE daily email newsletter.